NightstaRx Raises $45M to Fund Phase III Study with Retinal Disease Gene Therapy – Genetic Engineering & Biotechnology News (blog)
|
NightstaRx Raises $45M to Fund Phase III Study with Retinal Disease Gene Therapy
Genetic Engineering & Biotechnology News (blog) U.K. firm NightstaRx raised $45 million in a Series C financing round to support continued clinical development of its pipeline of retinal gene therapies, including a pending Phase III study with lead candidate NSR-REP1 for treating choroideremia. The … |
